ライフサイエンスコーパス: serious adverse

1 Glucocorticoid (GC)-induced ocular hypertension (OHT) is a serious adverse effect of prolonged GC therapy that can lead

2 ical pathways through which clozapine may act to cause this serious adverse effect.

3 -4 adverse event (29 [13%] of 223 vs 141 [64%] of 219) or a serious adverse event (11 [5%] of 223 vs 63 [29%] of 219).

4 One serious adverse event (transient atrial fibrillation) occurre

5 The most common serious adverse event in the active surveillance group was my

6 No serious adverse event occurred in more than one participant a

7 6 months (interquartile range, 20-30 mo), no patients had a serious adverse event or relapse of vasculitis.

8 ated ramucirumab and 54 (20%) of 265 assigned placebo had a serious adverse event that was judged by the investigator to

9 orted intestinal adhesions with obstruction as a severe and serious adverse event, which was considered as unrelated to s

10 Six uncontrolled studies reported low rates of death and serious adverse events (0% to 1.25%) in nontransported patien

11 17 serious adverse events (3%) were reported during the study: o

12 sus 23 (16%) of 140 in the placebo group; the most frequent serious adverse events (affecting >/=2% of patients) were ele

13 There was no significant difference in the incidence of serious adverse events (RR: 1.02; 95% CI: 0.94 to 1.09) or re

14 Criteria for IS contraindications were predefined and serious adverse events (SAEs) were reported to ethics committ

15 %] in the soft-tissue sarcoma group) had treatment-emergent serious adverse events (SAEs), five of whom had immune-relate

16 er design and are underpowered to identify risk factors for serious adverse events (SAEs), thereby limiting their influen

17 No other serious adverse events attributable to angiotensin II were re

18 upport the absence of large differences in risk of systemic serious adverse events between these two anti-VEGF drugs; i.e

19 Overall and serious adverse events did not differ between the flecainide

20 The overall rate of serious adverse events did not differ between treatment group

21 atitis, pancreatic cancer, medullary thyroid carcinoma, and serious adverse events did not differ significantly between t

22 events recorded, were febrile neutropenia (27 [17%] of 155 serious adverse events in patients who received doxorubicin a

23 ts in patients who received doxorubicin and 15 [12%] of 130 serious adverse events in patients who received gemcitabine a

24 Drug-related serious adverse events occurred in 28 (38%) of 74 patients.

25 Five serious adverse events occurred in 4 cases (15%), including p

26 Eight serious adverse events occurred in each group.

27 There were no serious adverse events or discontinuations due to adverse eve

28 n serious adverse events, representing 111 (39%) of all 285 serious adverse events recorded, were febrile neutropenia (27

29 The most common serious adverse events that occurred through week 24 were ana

30 The most common serious adverse events were anaemia (eight [4%]), upper gastr

31 Thirteen serious adverse events were identified among recipients of HR

32 11 serious adverse events were reported in seven (25%) patients

33 Three serious adverse events were reported, all in patients in the

34 Treatment-related serious adverse events were similar between groups (13 [11%]

35 The incidences of blood-product use, infection, and serious adverse events, as well as 28-day mortality, did not

36 Seven (44%) of 16 patients had serious adverse events, most of which were related to the und

37 There were no treatment-related serious adverse events, no treatment-related unsolicited grad

38 No discontinuations occurred because of adverse events, serious adverse events, or deaths in patients who received la

39 The three most common serious adverse events, representing 111 (39%) of all 285 ser

40 hotic patients relapsed and 2 discontinued treatment due to serious adverse events.

41 Study drugs were well tolerated with no serious adverse events.

42 tis (n=7; 23%) and fall (n=6; 20%); four patients (13%) had serious adverse events.

43 rapid, point-of-care identification of persons at risk for serious adverse events.

44 Six (3%) patients had 11 serious adverse events: one (2%) patient in the placebo group

45 y injury within 30 days after surgery; delirium; mortality; serious adverse events; and neurocognition.

46 12 patients reported serious adverse events; haemolysis and pyrexia were the most

47 Two (1%) of 166 patients had serious adverse events; neither were considered related to st

48 alth Initiative that hormone therapy use is associated with serious adverse health effects in postmenopausal women, use o

49 One unexpected, possibly related, serious adverse reaction that occurred 7 days after a 640 mug

50 No serious adverse reactions were recorded and other safety meas